Pharmacological properties of racemic chlorobromofosfamide.
Racemic chlorobromofosfamide (CBM-4A) is a bromine substituted analog of ifosfamide. The studies reported here were aimed at establishing the general pharmacological properties and toxicologic profile of this compound. Acute and cumulative toxicity, behavioral screening tests and effects of subchronic and chronic treatment (influence on body weight, mortality, blood morphology, proteins level, urea and creatinine concentration, enzymes activity) were taken into account. Summarized data revealed that CBM-4A possessed similar properties as other oxazaphosphorine cytostatics.
Juszkiewicz
M
M
Department of Pharmacology, Medical Academy, Lublin, Poland.
Kleinrok
Z
Z
Sawiniec
Z
Z
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D001798:Blood Proteins / Q000187:drug effects / Q000378:metabolism; D001831:Body Temperature / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006400:Hematocrit; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D007069:Ifosfamide / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D051381:Rats; D017208:Rats, Wistar; D013237:Stereoisomerism
D000970:Antineoplastic Agents; D001798:Blood Proteins; D006454:Hemoglobins; C097983:chlorobromofosfamide; D007069:Ifosfamide